메뉴 건너뛰기




Volumn 10, Issue 3, 2012, Pages 256-261

Week 96 outcomes of patients with less treatment experience versus more treatment experience receiving etravirine in the DUET trials

Author keywords

Antiretroviral; Clinical trials; Efficacy; Etravirine; HIV; Treatment experienced

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; PLACEBO;

EID: 84861168884     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212800618110     Document Type: Article
Times cited : (3)

References (5)
  • 2
    • 78649971571 scopus 로고    scopus 로고
    • Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials
    • Katlama C, Clotet B, Mills A, et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antiviral therapy 2010; 15(7): 1045-52.
    • (2010) Antiviral Therapy , vol.15 , Issue.7 , pp. 1045-1052
    • Katlama, C.1    Clotet, B.2    Mills, A.3
  • 3
    • 70449368908 scopus 로고    scopus 로고
    • Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: Pooled 48 week analysis of two randomised, controlled trials
    • Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomised, controlled trials. AIDS (London, England) 2009; 23(17): 2289-300.
    • (2009) AIDS (London, England) , vol.23 , Issue.17 , pp. 2289-2300
    • Katlama, C.1    Haubrich, R.2    Lalezari, J.3
  • 4
    • 79959470960 scopus 로고    scopus 로고
    • Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatmentexperienced patients
    • Schapiro JM, Boucher CA, Kuritzkes DR, et al. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatmentexperienced patients. Antiviral therapy 2011; 16(3): 395-404.
    • (2011) Antiviral Therapy , vol.16 , Issue.3 , pp. 395-404
    • Schapiro, J.M.1    Boucher, C.A.2    Kuritzkes, D.R.3
  • 5
    • 78049438484 scopus 로고    scopus 로고
    • Impact of the background regimen on virologic response to etravirine: Pooled 48-week analysis of DUET-1 and -2
    • Trottier B, Di Perri G, Madruga JV, et al. Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2. HIV clinical trials 2010; 11(4): 175-85.
    • (2010) HIV Clinical Trials , vol.11 , Issue.4 , pp. 175-185
    • Trottier, B.1    Di Perri, G.2    Madruga, J.V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.